查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1869950

生物相似药市场规模、份额和趋势分析报告：按药物类别、适应症、最终用途、地区和细分市场预测（2025-2033 年）

Biosimilars Market Size, Share & Trends Analysis Report By Drug Class (Monoclonal Antibodies (mAbs), Growth Factors & Hematopoietic Agents), By Indication, By End Use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

生物相似药市场摘要

2024年全球生物相似药市场规模估计为3,392万美元，预计2033年将达到1.5158亿美元。

预计从 2025 年到 2033 年，该市场将以 18.27% 的复合年增长率成长。生物相似药的成本效益和全球慢性病盛行率的不断上升是推动该市场成长的主要因素。

此外，这些药物易于生产，研发投入相对较低，且疗效与原厂药相当，可降低医疗成本。同时，生产成本的降低和需求的成长可能会促使生产商转向生物相似药以提高利润，进一步刺激市场发展。生物相似药可能含有略有不同的物质或药物成分组合，但在疗效和安全性方面与原厂生物製药相似。

目前有多项法规用于评估生物相似药的适用性和安全性。例如，美国食品药物管理局(FDA) 的简略新药申请流程要求申请人以科学方式证明其产品的性能与参考生物製药相当。这可以透过证明其产品与原厂药在相似的时间内进入血液循环来体现。这些法规有助于建立公众对生物相似药的信任，并提高其市场份额。

此外，全球慢性病和非传染性疾病盛行率的不断上升预计将推动市场成长。根据世界卫生组织（世卫组织）2023年11月发布的统计数据，癌症、糖尿病和心臟病等非传染性疾病每年导致4,100万人死亡，其中77%发生在低收入和中等收入国家。

美国食品药物管理局（FDA）预计2022年核准三种癌症生物相似药，并于2023年上市。这些不断扩大的市场机会正促使主要企业加大对生物相似药研发的投入。例如，根据《今日商业》2022年4月发表的报导报道，百康生物製药公司计划将其研发支出增加10-15%，以推进其生物类似药产品线的研发。此举预计将在未来巩固该公司的市场地位。生物相似药的研发在製药业正蓬勃发展。

目录

第一章调查方法和范围

第二章执行摘要

第三章 生物相似药市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析—波特五力分析
    • PESTLE分析
    • 管道分析

第四章 生物相似药市场：药物类别业务分析

  • 2024 年及 2033 年各药物类别市占率
  • 药物类别细分仪表板
  • 按药物类别分類的市场规模、预测和趋势分析，2021-2033年
  • 单株抗体（mAbs）
  • 生长因子和造血因子
  • 胰岛素及其类似物
  • 骨质疏鬆症/促进骨骼代谢的药物
  • 其他的

第五章 生物相似药市场：适应症业务分析

  • 适应症市场份额，2024 年和 2033 年
  • 指示细分仪表板
  • 市场规模、预测与趋势分析（按指标，2021-2033 年）
  • 自体免疫疾病（类风湿性关节炎、发炎性肠道疾病、干癣、僵直性脊椎炎）
  • 肿瘤科（乳癌、结肠癌、淋巴瘤、肺癌、胃癌）
  • 糖尿病（1 型和 2 型）
  • 眼科疾病（渗出性老龄化黄斑部病变、糖尿病视网膜病变、眼睑下垂）
  • 血液疾病/罕见血液疾病
  • 其他的

第六章 生物相似药市场：终端用户业务分析

  • 2024 年及 2033 年最终用户市场份额
  • 最终用户细分仪表板
  • 按最终用途分類的市场规模、预测和趋势分析（2021-2033 年）
  • 医院
  • 专科药房
  • 线上和零售通路

第七章 生物相似药市场：区域估算与趋势分析

  • 2024 年及 2033 年区域市占率分析
  • 区域市场概览
  • 市场规模及预测趋势分析（2021-2033）：
  • 北美洲
    • 按国家/地区划分，2021-2033 年
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争情势

  • 参与者概览
  • 企业市场分析
  • 公司分类
  • 策略规划
  • 公司简介/上市公司
    • Amgen Inc.
    • F Hoffman-La Roche Ltd
    • Sandoz International GmbH
    • Dr. Reddy's Laboratories
    • Teva Pharmaceutical Industries Ltd
    • Pfizer Inc.
    • Samsung Biopis
    • Biocon
    • Viatris Inc.
    • Celltrion Healthcare Co.Ltd
    • AbbVie Inc.
Product Code: 978-1-68038-916-6

Biosimilars Market Summary

The global biosimilars market size was estimated at USD 33.92 million in 2024 and is projected to reach USD 151.58 million by 2033, growing at a CAGR of 18.27% from 2025 to 2033. The cost-effectiveness of biosimilar drugs and the prevalence of chronic disorders globally are major factors contributing to market growth.

In addition, these drugs are comparatively easy to produce since they require less investment in research and development while providing similar results. This can help cut down expenditures on health. Moreover, the reduction in production costs and increasing demand can encourage producers to shift to biosimilars due to increased profits, which can give a further boost to this market. Biosimilars may contain slightly different substances and combinations of medical ingredients, but they are considered similar to their reference biologics in terms of effectiveness and safety.

Several regulations are in place to assess the compatibility and safety of biosimilar drugs. For instance, the FDA's Abbreviated New Drug Application Process requires applicants to scientifically prove that the performance of their product is similar to the reference biologics. It can be demonstrated by proving that their product takes a similar time to reach the bloodstream as the original product. Such regulations can help build trust in these drugs and expand their market share.

Moreover, the increasing prevalence of chronic or non-communicable diseases across the globe is also expected to drive the market. According to statistics released by the World Health Organization in November 2023, non-communicable diseases, such as cancer, diabetes, and heart diseases, cause 41 million deaths every year, out of which 77% of fatalities belong to low- and middle-income countries.

The U.S. FDA approved three cancer-related biosimilars in 2022, which are expected to hit the market in 2023. These growing opportunities in this market are also encouraging key players to increase their investment in the research and development of biosimilars. For instance, according to an article published in Business Today in April 2022, Biocon Biologics planned to increase its R&D expenses by 10% to 15% to advance its pipeline of biosimilar molecules. The step is expected to help strengthen its future position in the market. There is a boom in the pharmaceutical industry in the development of biosimilar medications.

Global Biosimilars Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global biosimilars market report based on drug class, indication, end use and region:

  • Drug Class Outlook (Revenue, USD Billion, 2021 - 2033)
  • Monoclonal Antibodies (mAbs)
  • Growth Factors & Hematopoietic Agents
  • Insulin & Analogues
  • Osteoporosis / Bone Metabolism Agents
  • Others
  • Indication Outlook (Revenue, USD Billion, 2021 - 2033)
  • Autoimmune Disorders (RA, IBD, Psoriasis, Ankylosing Spondylitis)
  • Oncology (Breast, Colorectal, Lymphoma, Lung, Gastric)
  • Diabetes Mellitus (Type 1 & Type 2)
  • Ophthalmic Disorders (Wet AMD, DME, RVO)
  • Hematologic / Rare Blood Disorders
  • Others
  • End Use Outlook (Revenue, USD Billion, 2021 - 2033)
  • Hospitals
  • Specialty Pharmacies
  • Online & Retail Channels
  • Regional Outlook (Revenue, USD Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwaita

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Indication
    • 1.2.3. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Biosimilars Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis

Chapter 4. Biosimilars Market: Drug Class Business Analysis

  • 4.1. Drug Class Market Share, 2024 & 2033
  • 4.2. Drug Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Billion)
  • 4.4. Monoclonal Antibodies (mAbs)
    • 4.4.1. Monoclonal Antibodies (mAbs) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.5. Growth Factors & Hematopoietic Agents
    • 4.5.1. Growth Factors & Hematopoietic Agents Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.6. Insulin & Analogues
    • 4.6.1. Insulin & Analogues Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.7. Osteoporosis / Bone Metabolism Agents
    • 4.7.1. Osteoporosis / Bone Metabolism Agents Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.8. Others
    • 4.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 5. Biosimilars Market: Indication Business Analysis

  • 5.1. Indication Market Share, 2024 & 2033
  • 5.2. Indication Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Billion)
  • 5.4. Autoimmune Disorders (RA, IBD, Psoriasis, Ankylosing Spondylitis)
    • 5.4.1. Autoimmune Disorders (RA, IBD, Psoriasis, Ankylosing Spondylitis) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.5. Oncology (Breast, Colorectal, Lymphoma, Lung, Gastric)
    • 5.5.1. Oncology (Breast, Colorectal, Lymphoma, Lung, Gastric) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.6. Diabetes Mellitus (Type 1 & Type 2)
    • 5.6.1. Diabetes Mellitus (Type 1 & Type 2) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.7. Ophthalmic Disorders (Wet AMD, DME, RVO)
    • 5.7.1. Ophthalmic Disorders (Wet AMD, DME, RVO) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.8. Hematologic / Rare Blood Disorders
    • 5.8.1. Hematologic / Rare Blood Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.9. Others
    • 5.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 6. Biosimilars Market: End Use Business Analysis

  • 6.1. End Use Market Share, 2024 & 2033
  • 6.2. End Use Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Billion)
  • 6.4. Hospitals
    • 6.4.1. Hospitals Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.5. Specialty Pharmacies
    • 6.5.1. Specialty Pharmacies Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.6. Online & Retail Channels
    • 6.6.1. Online & Retail Channels Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 7. Biosimilars Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America Biosimilars Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Billion)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Type Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Type Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. Canada Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Type Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.5. Europe
    • 7.5.1. Europe Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Type Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. UK Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Type Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Type Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Type Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Type Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Type Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Type Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Type Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Type Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Type Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Type Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Type Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Type Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Type Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.7. Latin America
    • 7.7.1. Latin America Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Type Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Brazil Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Type Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. Argentina Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Type Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Type Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Type Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Type Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Amgen Inc.
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. F Hoffman-La Roche Ltd
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Sandoz International GmbH
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Dr. Reddy's Laboratories
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Teva Pharmaceutical Industries Ltd
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Pfizer Inc.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Samsung Biopis
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Biocon
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Viatris Inc.
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Celltrion Healthcare Co.Ltd
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. AbbVie Inc.
      • 8.5.11.1. Overview
      • 8.5.11.2. Financial Performance
      • 8.5.11.3. Product Benchmarking
      • 8.5.11.4. Strategic Initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviations
  • Table 3 Global Biosimilars Market, By Region, 2021 - 2033 (USD Billion)
  • Table 4 Global Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 5 Global Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 6 Global Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 7 North America Biosimilars Market, By Country, 2021 - 2033 (USD Billion)
  • Table 8 North America Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 9 North America Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 10 North America Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 11 US Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 12 US Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 13 US Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 14 Canada Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 15 Canada Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 16 Canada Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 17 Mexico Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 18 Mexico Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 19 Mexico Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 20 Europe Biosimilars Market, By Country, 2021 - 2033 (USD Billion)
  • Table 21 Europe Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 22 Europe Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 23 Europe Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 24 UK Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 25 UK Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 26 UK Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 27 Germany Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 28 Germany Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 29 Germany Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 30 France Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 31 France Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 32 France Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 33 Italy Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 34 Italy Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 35 Italy Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 36 Spain Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 37 Spain Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 38 Spain Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 39 Norway Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 40 Norwa Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 41 Norwa Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 42 Denmark Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 43 Denmark Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 44 Denmark Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 45 Sweden Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 46 Swede Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 47 Swede Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 48 Asia Pacific Biosimilars Market, By Country, 2021 - 2033 (USD Billion)
  • Table 49 Asia Pacific Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 50 Asia Pacific Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 51 Asia Pacific Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 52 Japan Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 53 Japan Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 54 Japan Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 55 China Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 56 China Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 57 China Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 58 India Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 59 India Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 60 India Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 61 Australia Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 62 Australia Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 63 Australia Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 64 South Korea Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 65 South Korea Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 66 South Korea Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 67 Thailand Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 68 Thailand Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 69 Thailand Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 70 Latin America Biosimilars Market, By Country, 2021 - 2033 (USD Billion)
  • Table 71 Latin America Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 72 Latin America Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 73 Latin America Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 74 Brazil Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 75 Brazil Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 76 Brazil Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 77 Argentina Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 78 Argentina Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 79 Argentina Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 80 Middle East & Africa Biosimilars Market, By Country, 2021 - 2033 (USD Billion)
  • Table 81 Middle East & Africa Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 82 Middle East & Africa Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 83 Middle East & Africa Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 84 South Africa Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 85 South Africa Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 86 South Africa Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 87 Saudi Arabia Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 88 Saudi Arabia Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 89 Saudi Arabia Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 90 UAE Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 91 UAE Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 92 UAE Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 93 Kuwait Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 94 Kuwait Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 95 Kuwait Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)

List of Figures

  • Fig. 1 Biosimilars market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and disease outlook (USD Billion)
  • Fig. 10 Competitive landscape
  • Fig. 11 Biosimilars market dynamics
  • Fig. 12 Biosimilars market: Porter's five forces analysis
  • Fig. 13 Biosimilars market: PESTLE analysis
  • Fig. 14 Drug Class market, 2021 - 2033 (USD Billion)
  • Fig. 15 Monoclonal Antibodies (mAbs) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 16 Growth Factors & Hematopoietic Agents Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 17 Insulin & Analogues Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 18 Osteoporosis / Bone Metabolism Agents Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 19 Others Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 20 Indication market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 21 Autoimmune Disorders (RA, IBD, Psoriasis, Ankylosing Spondylitis) market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 22 Oncology (Breast, Colorectal, Lymphoma, Lung, Gastric) market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 23 Diabetes Mellitus (Type 1 & Type 2) market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 24 Ophthalmic Disorders (Wet AMD, DME, RVO) market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 25 Hematologic / Rare Blood Disorders market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 26 Others market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 27 End Use market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 28 Hospitals market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 29 Specialty Pharmacies market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 30 Online & Retail Channels market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 31 Biosimilars market revenue, by region
  • Fig. 32 Regional marketplace: Key takeaways
  • Fig. 33 North America biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 34 US country dynamics
  • Fig. 35 US biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 36 Canada country dynamics
  • Fig. 37 Canada biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 38 Mexico country dynamics
  • Fig. 39 Mexico biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 40 Europe biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 41 UK country dynamics
  • Fig. 42 UK biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 43 Germany country dynamics
  • Fig. 44 Germany biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 45 France country dynamics
  • Fig. 46 France biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 47 Italy country dynamics
  • Fig. 48 Italy biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 49 Spain country dynamics
  • Fig. 50 Spain biosimilars market, 2021 - 2033 (USD Billion)
  • Fig. 51 Norway country dynamics
  • Fig. 52 Norway biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 53 Sweden country dynamics
  • Fig. 54 Sweden biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 55 Denmark country dynamics
  • Fig. 56 Denmark biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 57 Asia Pacific biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 58 Japan country dynamics
  • Fig. 59 Japan biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 60 China country dynamics
  • Fig. 61 China biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 62 India country dynamics
  • Fig. 63 India biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 64 Australia country dynamics
  • Fig. 65 Australia biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 66 South Korea country dynamics
  • Fig. 67 South Korea biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 68 Thailand country dynamics
  • Fig. 69 Thailand biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 70 Latin America biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 71 Brazil country dynamics
  • Fig. 72 Brazil biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 73 Argentina country dynamics
  • Fig. 74 Argentina biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 75 MEA biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 76 South Africa country dynamics
  • Fig. 77 South Africa biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 78 Saudi Arabia country dynamics
  • Fig. 79 Saudi Arabia biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 80 UAE country dynamics
  • Fig. 81 UAE biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 82 Kuwait country dynamics
  • Fig. 83 Kuwait biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 84 Company categorization
  • Fig. 85 Company market position analysis
  • Fig. 86 Strategic framework